Experience in the use of clobazam in the treatment of Lennox–Gastaut syndrome
| Autor: | Gabriela Purcarin, Yu-Tze Ng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Neurological Disorders, Vol 7 (2014) |
| Druh dokumentu: | article |
| ISSN: | 1756-2856 1756-2864 17562856 |
| DOI: | 10.1177/1756285614521314 |
| Popis: | Clobazam is a 1,5-benzodiazepine used successfully worldwide since the 1970s as an anxiolytic and antiepileptic drug. Since its recent Food and Drug Administration (FDA) approval in the United States in 2011 as adjunctive treatment for Lennox–Gastaut syndrome, it has continued to show sustained efficacy and a better safety and tolerability profile compared with other benzodiazepines. The two randomized, controlled studies that led to the US FDA approval, as well as the follow-up multicenter, open-label study of clobazam, showed ≥50% seizure reduction for more than 50% of Lennox–Gastaut syndrome patients, while none of the other FDA-approved treatments for LGS have demonstrated efficacy rates better than 50%. Clobazam appears to have a safe profile and sustained effectiveness over the first 3 years of use in LGS and other epilepsy syndromes with intractable seizures, which makes it a viable long-term treatment option. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|